Company intelligence / Profile preview
Neurocarrus
Lincoln, Nebraska, United Statesneurocarrus.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Preclinical
01
Overview
Neurocarrus has developed a novel biologic drug candidate, N-001, which safely disrupts peripheral pain signals by targeting actin structures within sensory neurons. This approach avoids addiction risk and does not impair motor function. The company has generated extensive preclinical efficacy and safety data but has not yet entered clinical trials. No published human clinical results as of June 2025.
- Therapeutic areas
- Neurology
- Modalities
- ProteinBiologicDrug delivery technology (novel protein-based)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Neurocarrus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurocarrus.